The effect of early treatment by cerivastatin on the serum level of C-reactive protein, interleukin-6, and interleukin-8 in the patients with unstable angina and non-Q-wave myocardial infarction

  • Petr Ostadal
  • David Alan
  • Petr Hajek
  • David Horak
  • Jiri Vejvoda
  • Jiri Trefanec
  • Martin Mates
  • Jan Vojacek
Part of the Molecular and Cellular Biochemistry: An International Journal for Chemical Biology in Health and Disease book series (DMCB, volume 41)


The aim of our study was to evaluate whether a single dose of cerivastatin at the time of admission of patients with unstable angina pectoris (UAP) or non-Q-wave myocardial infarction (NQMI) can influence the serum level of C-reactive protein (CRP), interleukin-6 (IL-6) and interleukin-8 (IL-8) 24 h later. Forty-four patients with rest chest pain and subendocardial ischemia on ECG were randomized to receive cerivastatin 0.3 mg at the time of admission (group C+) to standard therapy or to remain just on standard therapy (group C—). Blood samples for determination of troponin I (TI), CRP, IL-6 and IL-8 were collected at admission (entry level) and 24 h later (final level). Patients with non-physiological baseline levels of TI, as well as patients with progression to Q wave MI were excluded. All baseline, clinical and demographic data and final values of TI were comparable in the two groups. In patients treated with cerivastatin (group C+ n =13) we observed decrease in the CRP level (-6.73

3.93 mg/L); on the other hand, in group C- (n =17) the CRP level increased (+7.92 ± 2.77 mg/L, p = 0.004). Similar differences were observed also in IL-6: in group C+ the level was significantly reduced as compared with the increase in group C-(-0.76 ± 0.52 vs. 4.58 ± 1.49 ng/L, p = 0.005). The level of IL-8 was not affected. Our results suggest that early treatment with cerivastatin can decrease the serum level of CRP and IL-6 in patients with UAP/NQMI; this might positively influence their prognosis. Nevertheless, further studies are needed to support this hypothesis. (Mol Cell Biochem246:45-50, 2003)

Key words:

cerivastatin inflammation C-reactive protein interleukin unstable angina myocardial infarction 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Whicher J, Biasucci L, Rifai N: Inflammation, the acute phase response and atherosclerosis. Clin Chem Lab Med 37: 495–503,1999PubMedCrossRefGoogle Scholar
  2. 2.
    Barath P, Fishbein MC, Cao J, Berenson J, Helfant RH, Forrester JS: Detection and localization of tumor necrosis factor in human atheroma. Am J Cardiol 65: 297–302,1990PubMedCrossRefGoogle Scholar
  3. 3.
    Semen GG, Abbate R, Gori AM, Attanasio M, Martini F, Giusti B et al.: Transient intermittent lymphocyte activation is responsible for the instability of angina. Circulation 86: 790–797,1992CrossRefGoogle Scholar
  4. 4.
    Biasucci LM, Vitelli A, Liuzzo G, Altamura S, Caligiuri G, Monaco C et al.: Elevated levels of interleukin-6 in unstable angina. Circulation 94: 874–877,1996PubMedCrossRefGoogle Scholar
  5. 5.
    Blake GJ, Ridker PM: Novel clinical markers of vascular wall inflammation. Circ Res 89: 763–771,2001PubMedCrossRefGoogle Scholar
  6. 6.
    Morrow DA, Rifai N, Antman EM, Weiner DL, McCabe CH, Cannon CP et al.: C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: A TIMI I1A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 31: 1460–1465,1998PubMedCrossRefGoogle Scholar
  7. 7.
    Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB: Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 349: 462–466,1997PubMedCrossRefGoogle Scholar
  8. 8.
    Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB et al.: The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 331: 417–424, 1994PubMedCrossRefGoogle Scholar
  9. 9.
    Rifai N, Ridker PM. High-sensitivity C-reactive protein: A novel and promising marker of coronary heart disease. Clin Chem 47: 403–411, 2001PubMedGoogle Scholar
  10. 10.
    Goldstein JL, Brown MS: Regulation of the mevalonate pathway. Nature 343: 425–430.1990PubMedCrossRefGoogle Scholar
  11. 11.
    The Scandinavian Simvastatin Survival Study (4S): Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 344: 1383–1389,1994Google Scholar
  12. 12.
    Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335: 1001–1009,1996PubMedCrossRefGoogle Scholar
  13. 13.
    Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333: 1301–1307,1995PubMedCrossRefGoogle Scholar
  14. 14.
    Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S et al.: Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 98: 839–844,1998PubMedCrossRefGoogle Scholar
  15. 15.
    Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS et al.: Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl Med 344: 1959–1965,2001CrossRefGoogle Scholar
  16. 16.
    Romano M, Diomede L, Sironi M, Massimiliano L, Sottocorno M, Polentarutti N et al.: Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest 80: 1095–1100,2000PubMedCrossRefGoogle Scholar
  17. 17.
    Ikeda U, Shimpo M, Ohki R, Inaba H, Takahashi M, Yamamoto K et al.: Fluvastatin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells. Hypertension 36: 325–329,2000PubMedCrossRefGoogle Scholar
  18. 18.
    Fukumoto Y, Libby P, Rabkin E, Hill CC, Enomoto M, Hirouchi Y et al.: Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation 103: 993–999,2001PubMedCrossRefGoogle Scholar
  19. 19.
    Brull DJ, Sanders J, Rumley A, Lowe GD, Humphries SE, Montgomery HE: Statin therapy and the acute inflammatory response after coronary artery bypass grafting. Am J Cardiol 88: 431–433,2001PubMedCrossRefGoogle Scholar
  20. 20.
    Niwa S, Totsuka T, Hayashi S: Inhibitory effect of fluvastatin, an HMGCoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line. Int J Immunopharmacol 18: 669–675,1996PubMedCrossRefGoogle Scholar
  21. 21.
    Ikeda U, Shimada K: Statins and monocytes. Lancet 353: 2070,1999PubMedCrossRefGoogle Scholar
  22. 22.
    Rosenson RS, Tangney CC, Casey LC: Inhibition of proinflammatory cytokine production by pravastatin. Lancet 353: 983–984,1999PubMedCrossRefGoogle Scholar
  23. 23.
    Ferro D, Parrotto S, Basili S, Alessandri C, Violi F: Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J Am Coll Cardiol 36: 427–431,2000PubMedCrossRefGoogle Scholar
  24. 24.
    Bustos C, Hernandez-Presa MA, Ortego M, Tunon J, Ortega L, Perez F et al.: HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 32: 2057–2064,1998PubMedCrossRefGoogle Scholar
  25. 25.
    Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D et al.: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. JAMA 285: 1711–1718,2001PubMedCrossRefGoogle Scholar
  26. 26.
    Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS et al.: ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 36: 970–1062,2000PubMedCrossRefGoogle Scholar
  27. 27.
    Inoue I, Goto S, Mizotani K, Awata T, Mastunaga T, Kawai S et al.: Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: Reduction of MRNA levels for interleukin- 1 beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells. Life Sci 67: 863–876, 2000PubMedCrossRefGoogle Scholar
  28. 28.
    Ando H, Takamura T, Ota T, Nagai Y, Kobayashi K: Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. J Pharmacol Exp Ther 294: 1043–1046, 2000PubMedGoogle Scholar
  29. 29.
    Albert MA, Danielson E, Rifai N, Ridker PM: Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study. JAMA 286: 64–70, 2001PubMedCrossRefGoogle Scholar
  30. 30.
    Horne BD, Muhlestein JB, Carlquist JF, Bair TL, Madsen TE, Hart NI et al.: Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease. J Am Coll Cardiol 36: 1774–1780, 2000PubMedCrossRefGoogle Scholar
  31. 31.
    Strandberg TE, Vanhanen H, Tikkanen MJ. Effect of statins on C-reactive protein in patients with coronary artery disease. Lancet 353: 118–119, 1999PubMedCrossRefGoogle Scholar
  32. 32.
    halal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S: Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 103: 1933–1935, 2001CrossRefGoogle Scholar
  33. 33.
    Ridker PM, Rifai N, Lowenthal SP: Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 103: 1191–1193, 2001PubMedCrossRefGoogle Scholar
  34. 34.
    Deskur-Smielecka E, Wykr TA, Kempa M, Furmaniuk J, Wysocki H: The influence of short-term treatment with simvastatin on the inflammatory profile of patients with hypercholesterolaemia. Coron Artery Dis 12: 143–148, 2001PubMedCrossRefGoogle Scholar
  35. 35.
    Takata M, Urakaze M, Temaru R, Yamazaki K, Nakamura N, Nobata Y et al.: Pravastatin suppresses the interleukin-8 production induced by thrombin in human aortic endothelial cells cultured with high glucose by inhibiting the p44/42 mitogen activated protein kinase. Br J Pharmacol 134: 753–762, 2001PubMedCrossRefGoogle Scholar
  36. 36.
    Kothe H, Dalhoff K, Rupp J, Muller A, Kreuzer J, Maass M et al.: Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae. Circulation 101: 1760–1763, 2000PubMedCrossRefGoogle Scholar
  37. 37.
    Terkeltaub R, Solan J, Barry M Jr, Santoro D, Bokoch GM: Role of the mevalonate pathway of isoprenoid synthesis in IL-8 generation by activated monocytic cells. J Leukoc Biol 55: 749–755, 1994PubMedGoogle Scholar
  38. 38.
    Koukkunen H, Penttila K, Kemppainen A, Halinen M, Penttila I, Rantanen T et al.: C-reactive protein, fibrinogen, interleukin-6 and tumour necrosis factor-alpha in the prognostic classification of unstable angina pectoris. Ann Med 33: 37–47, 2001PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2003

Authors and Affiliations

  • Petr Ostadal
    • 1
  • David Alan
    • 1
  • Petr Hajek
    • 1
  • David Horak
    • 1
  • Jiri Vejvoda
    • 1
  • Jiri Trefanec
    • 1
  • Martin Mates
    • 1
  • Jan Vojacek
    • 1
  1. 1.Department of Internal MedicineUniversity Hospital Motol and 2nd Medical Faculty, Charles University, PragueCzech Republic

Personalised recommendations